Abstract
Rationale: Progressive loss of muscle mass and function frequently accompanies chronic liver diseases (CLDs), and it has recently been clarified that the severity of sarcopenia is associated with clinical outcomes in these patients [1]. Thus, assessment of the decrease in muscle mass due to CLDs, especially before cirrhosis develops, would be valuable in the management of patients. The aim of this study, whose preliminary results are presented here, was to examine the relationship between muscle mass measurements and disease severity markers in patients with CLDs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
